Učinek jemanja zdravil, ki ojačijo serotoninergično transmisijo na motorične znake parkinsonove bolezni
| Autor: | PETRIŠIČ, MIHA |
|---|---|
| Přispěvatelé: | Sadikov, Aleksander |
| Jazyk: | slovinština |
| Rok vydání: | 2020 |
| Předmět: |
Parkinsonova bolezen
selective serotonin reuptake inhibitor Parkinson's disease depression motorični in nemotorični simptomi parkinsonove bolezni depresija motor and nonmotor symptoms of Parkinson's disease zdravila ki ojačijo serotoninergično transmisijo selektivni zaviralci ponovnega prevzema serotonina medication that enhance serotonergic transmission |
| Popis: | Depresija je ena izmed najpogostejših motenj pri bolnikih s parkinsonovo boleznijo (PB). Za lajšanje depresijskih motenj se pogosto uporabljajo zdravila, ki ojačijo serotoninergično transmisijo (ZOST). Kljub ugodnemu učinku teh zdravil na depresivno simptomatiko trenutno še ni znano, kako ta zdravila vplivajo na motorične znake PB. Za namene te študije smo uporabili podatke iz podatkovne zbirke študije Parkinson’s Progression Markers Initiative (PPMI). Gre za tekočo, longitudinalno študijo o različnih dejavnikih, ki morebiti lahko vplivajo na potek bolezni. V študijo smo vključili bolnike s PB, ki so prvič začeli jemati ZOST, med spremljanjem v sklopu omenjene študije. Uporabili smo demografske podatke ter podatke o motoričnem in nemotoričnem stanju 66 bolnikov pred začetkom in povprečno 237 dni po začetku jemanja tarčnih zdravil. To skupino bolnikov smo primerjali s kontrolno skupino 132 bolnikov, ki so se s tarčno skupino ujemali po motoričnem stanju pred začetkom jemanja tarčnih zdravil. Rezultati študije so pokazali, da kljub temu da se na začetku osebe v tarčni in kontrolni skupini ne razlikujejo med seboj, imajo bolniki po začetku jemanja ZOST statistično pomembno slabše motorično stanje oz. višje ocene na tretjem delu združene lestvice za oceno parkinsonove bolezni (ang. Movement Disorders Society-Unified Parkinson's Disease Rating Scale part III – MDS-UPDRS part III) v primerjavi z bolniki, ki teh zdravil niso jemali, predvsem na račun bradihipokinezije. Depression is one of the most common disorders in patients with Parkinson's disease (PD). Medication that enhance serotonergic transmission are often used to relieve depressive disorders. Despite the beneficial effect of these drugs on depressive symptoms, it is not yet known how these drugs affect the motor signs of PD. For the purposes of this study, we used data from the Parkinson’s Progression Markers Initiative (PPMI) study database. It is an ongoing, longitudinal study of various factors that could potentially affect the course of the disease. The study included patients with PD who first started taking medication that enhance serotonergic transmission during the study. We used demographic data and the motor and non-motor status of 66 patients before the start and on average 237 days after the start of taking target drugs. This group of patients was compared with a control group of 132 patients who matched the target group in terms of motor status before taking target drugs. The results of the study showed that despite the fact that at the beginning members of target and control group did not differ from each other, patients who started taking drugs that enhance serotonergic transmission have a statistically significantly worse motor condition/higher scores on the Movement Disorders Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS part III) compared to patients who did not take these drugs, mainly at the expense of worsened bradyhypokinesia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|